Health Catalyst Inc

Health Catalyst’s CEO buy‑type PRSU award shows performance‑linked leadership; investors watch upcoming earnings to gauge data‑analytics growth amid volatile stock.

CEO Albert Benjamin’s sell‑to‑cover of 70,455 Health Catalyst shares at $1.85 reflects routine tax‑withholding, not a strategic divestment, and shows insider sentiment amid weak fundamentals.

Health Catalyst insiders buy large RSU/PRS​U awards, signaling confidence despite volatile shares—an insider‑based signal for investors to track performance metrics and sector growth.

Health Catalyst insider buys RSUs at $1.72 low: director Duncan’s confidence hints at a rebound despite leadership churn and losses.